Financials data is unavailable for this security.
View more
Year on year Arch Biopartners Inc had net income fall 136.30% from a loss of 1.41m to a larger loss of 3.33m despite a 105.63% increase in revenues from 964.68k to 1.98m. An increase in the selling, general and administrative costs as a percentage of sales from 80.09% to 153.22% was a component in the falling net income despite rising revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -185.89% |
| Operating margin | -173.29% |
| Return on assets | -174.05% |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in CADView more
In 2023, Arch Biopartners Inc increased its cash reserves by 64.17%, or 324.92k. Cash Flow from Financing totalled 559.00k or 28.18% of revenues. In addition the company used 234.08k for operations while cash used for investing totalled .
| Cash flow per share | -0.0411 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -0.1021 |
|---|---|
| Tangible book value per share | -0.1021 |
More ▼
Balance sheet in CADView more
| Current ratio | 0.2026 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
